Global Lupus Therapeutic Market 2017-2021
About Lupus Therapeutic
Lupus is a chronic autoimmune disease in which the body's immune system becomes hyperactive and attacks normal, healthy tissue. This results in symptoms such as inflammation, swelling, and damage to joints, skin, kidneys, blood, the heart, and lungs. Systemic lupus erythematosus (SLE) is a major disease, which is followed by lupus nephritis at the later stages. Only one drug is approved specifically for the treatment of lupus disorders and the majority of other drugs are off-label based on symptoms. Due to a strong pipeline, the market is expected for more approved drugs for lupus disorders in future.
Technavio’s analysts forecast the global lupus therapeutic market to grow at a CAGR of 9.74% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global lupus therapeutic market for 2017-2021. To calculate the market size, the report considers both generic and branded drug market.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Lupus Therapeutic Market 2017-2021
Technavio recognizes the following companies as the key players in the global lupus therapeutic market 2017-2021: F.Hoffmann-La Roche, GlaxoSmithKline, Medlmmune, and Pfizer.
Other Prominent Vendors in the market are: ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer HealthCare, Biogen, Biotest, Bristol-Myers Squibb, Celgene, Immunomedics, Kedrion Biopharma, LFB Group, Merck, Novartis, Shire, Takeda Pharmaceuticals, and UCB.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is regenerative therapeutic technologies. The management of lupus using regenerative medicines is increasing, and many vendors are focusing on the development of regenerative medicines. The role of regenerative medicines in autoimmune disease is not explored completely. The recent studies showed that immunomodulation and suppression could be achieved through cellular interaction between therapeutic cells and the individual’s immune system, including anti-inflammatory T-cell responses.”
According to the report, one of the major drivers for this market is high prevalence rate. Lupus is one of the major autoimmune diseases that is associated with multiple symptoms like pain, extreme fatigue, hair loss, cognitive issues, and physical impairments, which disturbs every aspect of individual's lives.
Further, the report states that one of the major factors hindering the growth of this market is complexity of disease. Lupus is associated with multiple symptoms, which increases the complexity in individuals for diagnosis, treatment, and overall management. As per the Centers for Disease Control and Prevention (CDC), many individuals with lupus experiences severe inflammation and continuous damage, which leads to general fatigue, chronic pain, mood disturbances, poor sleep quality, and cognitive impairment. Fatigue is experienced by about 85%-92% of people living with lupus. The individuals with lupus can have a significantly lower quality of life than people with other chronic diseases due to its complexity.
F.Hoffmann-La Roche, GlaxoSmithKline, Medlmmune, Pfizer, ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer HealthCare, Biogen, Biotest, Bristol-Myers Squibb, Celgene, Immunomedics, Kedrion Biopharma, LFB Group, Merck, Novartis, Shire, Takeda Pharmaceuticals, and UCB.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook